SARS-CoV-2 Vaccination for Children—An Open Issue
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Logunov, D.Y.; Dolzhikova, I.V.; Zubkova, O.V. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. Lancet 2020, 396, 887–897. [Google Scholar] [CrossRef]
- Logunov, D.Y.; Dolzhikova, I.V.; Shcheblyakov, D.V.; Tukhvatulin, A.I.; Zubkova, O.V.; Dzharullaeva, A.S.; Kovyrshina, A.V.; Lubenets, N.L.; Grousova, D.M.; Erokhova, A.S.; et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021, 397, 671–681. [Google Scholar] [CrossRef]
- Zhu, F.C.; Li, Y.H.; Guan, X.H.; Hou, L.H.; Wang, W.J.; Li, J.X.; Wu, S.P.; Wang, B.S.; Wang, Z.; Wang, L.; et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020, 395, 1845–1854. [Google Scholar] [CrossRef]
- Zhang, Y.; Zeng, G.; Pan, H.; Li, C.; Hu, Y.; Chu, K.; Han, W.; Chen, Z.; Tang, R.; Yin, W.; et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021, 21, 181–192. [Google Scholar] [CrossRef]
- Gorry, C. SOBERANA, Cuba’s COVID-19 Vaccine Candidates: Dagmar García-Rivera PhD. MEDICC Rev. 2020, 22, 10–15. [Google Scholar]
- Castells, M.C.; Phillips, E.J. Maintaining Safety with SARS-CoV-2 Vaccines. N. Engl. J. Med. 2020, NEJMra2035343. [Google Scholar] [CrossRef]
- Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef]
- Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021, 384, 403–416. [Google Scholar] [CrossRef] [PubMed]
- European Centre for Disease Prevention and Control. Available online: https://qap.ecdc.europa.eu/public/extensions/COVID-19/COVID-19.html#vaccine-tracker-tab (accessed on 15 February 2021).
- Rasmussen, A.L. Vaccination is the Only Acceptable Path to Herd Immunity. Med. N. Y. 2020, 1, 21–23. [Google Scholar] [CrossRef] [PubMed]
- BBC News. Available online: https://www.bbc.com/news/world-europe-55666399 (accessed on 15 February 2021).
- Kadire, S.R.; Wachter, R.M.; Lurie, N. Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination. N. Engl. J. Med. 2021. [Google Scholar] [CrossRef]
- Klass, P.; Ratner, A.J. Vaccinating Children against Covid-19-The Lessons of Measles. N. Engl. J. Med. 2021, 384, 589–591. [Google Scholar] [CrossRef]
- Ludvigsson, J.F. The first eight months of Sweden’s COVID-19 strategy and the key actions and actors that were involved. Acta Paediatr. 2020, 109, 2459–2471. [Google Scholar] [CrossRef]
- Danis, K.; Epaulard, O.; Bénet, T.; Gaymard, A.; Campoy, S.; Botelho-Nevers, E.; Bouscambert-Duchamp, M.; Spaccaferri, G.; Ader, F.; Mailles, A.; et al. Investigation Team. Cluster of coronavirus disease 2019 (COVID-19) in the French Alps, 2020. Clin Infect Dis. 2020, 71, 825–832. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Caselli, D.; Aricò, M. 2019-nCoV: Polite with children! Pediatr. Rep. 2020, 12, 8495. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, Y.; Bloxham, C.J.; Hulme, K.D.; Sinclair, J.E.; Tong, Z.W.M.; Steele, L.E.; Noye, E.C.; Lu, J.; Xia, Y.; Chew, K.Y.; et al. A meta-analysis on the role of children in SARS-CoV-2 in household transmission clusters. Clin. Infect. Dis. 2020, ciaa1825. [Google Scholar] [CrossRef]
- Opel, D.J.; Diekema, D.S.; Ross, L.F. Should We Mandate a COVID-19 Vaccine for Children? JAMA Pediatr. 2021, 175, 125–126. [Google Scholar] [CrossRef]
- Riou, J.; Althaus, C.L. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill. 2020, 25, 2000058. [Google Scholar] [CrossRef] [PubMed]
- Washington State Board of Health, Immunization Advisory Committee. Criteria for reviewing antigens for potential inclusion in WAC 246-100-166. Available online: https://sboh.wa.gov/Portals/7/Doc/Publications/ImmunizationCriteria-Update2017-Final.pdf (accessed on 15 February 2021).
- Opel, D.J.; Diekema, D.S.; Marcuse, E.K. A critique of criteria for evaluating vaccines for inclusion in mandatory school immunization programs. Pediatrics 2008, 122, e504–e510. [Google Scholar] [CrossRef]
- Tönshoff, B.; Müller, B.; Elling, R.; Renk, H.; Meissner, P.; Hengel, H.; Garbade, S.F.; Kieser, M.; Jeltsch, K.; Grulich-Henn, J.; et al. Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany. JAMA Pediatr. 2021, e210001. [Google Scholar] [CrossRef]
- Ludvigsson, J.F.; Engerström, L.; Nordenhäll, C.; Larsson, E. Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden. N. Engl. J. Med. 2021, NEJMc2026670. [Google Scholar] [CrossRef]
- Haynes, B.F.; Corey, L.; Fernandes, P.; Gilbert, P.B.; Hotez, P.J.; Rao, S.; Santos, M.R.; Schuitemaker, H.; Watson, M.; Arvin, A. Prospects for a safe COVID-19 vaccine. Sci. Transl. Med. 2020, 12, eabe0948. [Google Scholar] [CrossRef] [PubMed]
- Castells, M.C.; Phillips, E.J. Maintaining Safety with SARS-CoV-2 Vaccines. Reply. N. Engl. J. Med. 2021. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Caselli, D.; Aricò, M. SARS-CoV-2 Vaccination for Children—An Open Issue. Pediatr. Rep. 2021, 13, 95-97. https://doi.org/10.3390/pediatric13010013
Caselli D, Aricò M. SARS-CoV-2 Vaccination for Children—An Open Issue. Pediatric Reports. 2021; 13(1):95-97. https://doi.org/10.3390/pediatric13010013
Chicago/Turabian StyleCaselli, Désirée, and Maurizio Aricò. 2021. "SARS-CoV-2 Vaccination for Children—An Open Issue" Pediatric Reports 13, no. 1: 95-97. https://doi.org/10.3390/pediatric13010013